Predicting potential epitopes of structural proteins for Alpha, Delta, and Omicron variants of SARS-CoV-2

Read full text Summarise with VIRAT
Authors: Diyantoro, Fedik Abdul Rantam, Juniastuti, Andi Yasmin Wijaya, Helen Susilowati, Suryo Kuncorojakti, Ahmad Aswin
Cited by: 0
References: 41

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Due to the emergence of highly transmissible variants, such as the recombinant subvariant XEC, SARS-CoV-2 continues to spread worldwide. Epitope-based vaccines have been developed since conventional antigen-based vaccines may not provide protection against all SARS-CoV-2 variants. These vaccines target multiple epitopes that interact with antibodies or T-cell receptors and are being investigated to enhance immune responses. Objective This study investigates the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 across different variants, including Alpha, Delta, and Omicron, to identify potential epitopes that could contribute to the development of next-generation vaccines. Methods This study used several freely accessible web-based tools and open source to identify the potential epitopes. Antigenicity, allergenicity, and toxicity prediction were evaluated using VaxiJen v2.0, AntigenPro, AllerTop v2.0, and ToxinPred. Cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and linear B lymphocyte (LBL) epitopes were predicted using the Immune Epitope Database (IEDB) server. Results VaxiJen v2.0 indicated that the E protein demonstrates lower antigenicity than the S, M, and N proteins among the selected variants. AntigenPro analysis revealed that in the Alpha (B.1), Delta (AY.23), and Omicron (BQ.1.23) variants, only the S and N proteins surpassed the antigenicity threshold. However, in the Omicron BA.5.2 and BA.1.1 variants, only the E protein was found to be below the threshold. Further analysis showed that only the S (17 CTL, 6 HTL, and 13 LBL) and N (7 CTL, 6 HTL, and 1 LBL) proteins contain potential T-and B-cell epitopes. Conclusions This study provides valuable insights into potential epitopes derived from various SARS-CoV-2 variants, which may be utilized for the development of epitope-based vaccines.

Fields of Study & Subjects

vaccines and immunoinformatics approaches SARS-CoV-2 and COVID-19 Research Immunotherapy and Immune Responses

Publication details

Journal / source
Heliyon
Volume
12
Issue
6
Pages
e44788–e44788
Publication date
31 March 2026
Language
EN